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Summary 
Background: Horizon Scanning in Oncology (HSO) was implemented by the 
Austrian Ludwig Boltzmann Institute for Health Technology Assessment 
(LBI-HTA) in 2009 due to increasing expenditures for anti-cancer therapies. 
Aim of HSO is to facilitate the evidence-based use of new anti-cancer drugs 
and to pre-estimate their financial implications. Thus, new anti-cancer 
drugs are evaluated before their routine introduction into clinical practice in 
order to inform decision-makers.  
Objective: The aim of this paper is to evaluate the impact of the program 
HSO. 
Methods: 3 methods were used to evaluate the impact of HSO.  
1. A download analysis of all HSO reports published on the website 
of the LBI-HTA.  
2. An online survey amongst recipients of email-alerts on the avail-
ability of new HSO reports.  
3. An environmental analysis to identify HTA institutes also per-
forming (early) assessments of anti-cancer drugs.  
Results:  
Download analysis: The websites of LBI-HTA’s HSO reports were viewed 
13,737 times and reports were downloaded in total 6,671 times between Oc-
tober 2009 and February 2012. On average, reports were downloaded 25 
times per month. 
Online survey: Out of 126 valid invitations sent to HSO email-alert recipi-
ents 36 participated in the survey (response rate: 29%). Most of the survey 
participants were pharmacists. 72% of the responders were involved in deci-
sion-making processes; 94% were satisfied with the structure and content of 
the report; 89% rated the total quality of the reports to be “very good” or 
“good”. 71% of the responders were using HSO reports, but mainly as an in-
formation source (rather than as decision support).  
Environmental analysis: A databases search (CRD HTA database, 
EUnetHTA, EuroScan and INAHTA) for the 24 drugs assessed by the LBI-
HTA within its program HSO identified the following organisations as also 
being involved in (early) assessment of anti-cancer drugs: IQWiG, NETSCC, 
NICE, NHSC and SMC. The screening of the websites of HTA institutes 
identified further 5 agencies having published (early) assessment reports: 
AKDAE, CADTH, CVZ, HAS and NCPE. 2 times the LBI-HTA was the 
only institute having published an early assessment report And besides the 
NHSC, the LBI-HTA was amongst the first HTA institutes publishing re-
ports on anti-cancer drugs - on average within 4 months after approval by 
the European Medicines Agency. 
Conclusion: In general there are indications for an impact of HSO: the re-
ports are increasingly downloaded and are considered (by those who re-
sponded to the survey) as a relevant, timely and high-quality information 
source. The environmental analysis showed that the LBI-HTA is with its 
early assessments of anti-cancer drugs amongst the earliest institutes pub-
lishing reports, on average, within 4 months after the European Medicines 
HSO for early 
identification and 
assessment of new anti-
cancer drugs 
objective: to evaluate 
the impact of HSO 
3 methods:  
download analysis, 
online survey and 
environmental analysis 
HSO reports have been 
downloaded 6,671 times 
71% of the survey 
participants used HSO 
reports 
LBI-HTA publishes its 
reports early – on 
average 4 months after 
EMA approval 
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Agency approval. Nevertheless several questions remain unanswered, as, for 
example, do the HSO documents actually have an influence on decisions or 
why do clinicians use this source less often? 
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Zusammenfassung 
Einleitung: Aufgrund steigender Ausgaben für Krebstherapien implemen-
tierte das österreichische Ludwig Boltzmann Institut für Health Technology 
Assessment (LBI-HTA) 2009 das Programm „Horizon Scanning in Oncolo-
gy“ (HSO). Ziel dieses Projekts ist, den evidenz-basierten Einsatz von neuen 
onkologischen Medikamenten zu ermöglichen und die finanziellen Auswir-
kungen abzuschätzen. Um EntscheidungsträgerInnen zu informieren, wer-
den deshalb neue onkologische Medikamente vor ihrer routinemäßigen Ein-
führung in den klinischen Alltag im Rahmen dieses Programms evaluiert. 
Zielsetzung: Das Ziel dieser wissenschaftlichen Arbeit ist, die Auswirkun-
gen (= Impact) des Programms HSO zu erheben. 
Methoden: 3 Methoden wurden angewandt, um die Auswirkungen von HSO 
zu erheben:  
1. Eine Download-Analyse der HSO Berichte, die auf der Webseite 
des LBI-HTA publiziert wurden. 
2. Eine Online-Umfrage unter EmpfängerInnen von E-Mail Be-
nachrichtigungen über die Verfügbarkeit neuer HSO Berichte.  
3. Eine Umfeldanalyse, um andere HTA Institute, die (Früh-) Be-
wertungen von onkologischen Medikamenten durchführen, zu er-
mitteln.  
Ergebnisse:  
Download-Analyse: Die Webseite HSO wurde zwischen Oktober 2009 und 
Februar 2012 insgesamt 13.737 Mal betrachtet und die Berichte wurden ins-
gesamt 6.671 Mal - im Durchschnitt 25 Mal pro Monat heruntergeladen. 
Online-Umfrage: Von 126 Einladungen, die an EmpfängerInnen der E-Mail 
Benachrichtigungen über neue HSO Berichte versandt wurden, nahmen 36 
an der Umfrage teil (Rücklaufquote: 29%). Die meisten Umfrage-
TeilnehmerInnen waren PharmazeutInnen. 72% der TeilnehmerInnen wa-
ren in Entscheidungsprozessen involviert; 94% waren zufrieden mit der 
Struktur und dem Inhalt der Berichte; 89% stuften die Gesamtqualität der 
Berichte als „sehr gut“ bis „gut“ ein. 71% der Befragten, also die Mehrzahl,  
verwendeten HSO Berichte als Informationsquelle (statt als Entscheidungs-
hilfe). 
Umfeldanalyse: Eine Datenbanksuche (CRD HTA Datenbank, EUnetHTA, 
EuroScan und INAHTA) nach den 24 Medikamenten, die vom LBI-HTA 
innerhalb des HSO Programms bewertet wurden, ermittelte folgende Orga-
nisationen, die auch Bewertungen von onkologischen Medikamenten durch-
führen: IQWiG, NETSCC, NICE, NHSC und SMC. Das Screening der 
Webseiten von HTA Instituten ergab weitere 5 Institute, die Bewertungen 
veröffentlichen: AKDAE, CADTH, CVZ, HAS und NCPE. Zwei Mal war 
das LBI-HTA das einzige Institut, welches Frühbewertungen publiziert hat-
te und, außer dem NHSC, sind die Berichte unter den am frühesten verfüg-
baren einzureihen - im Durchschnitt innerhalb von 4 Monaten nach der Zu-
lassung durch die European Medicines Agency. 
Schlussfolgerung: Generell gibt es Hinweise für einen Impact des HSO Pro-
gramms: die Berichte werden zunehmend heruntergeladen und werden als 
relevante, zeitgemäße und qualitative Informationsquelle betrachtet. Die 
HSO zur Fru¨herkennung 
und -evaluierung von 
Onkologika 
Zielsetzung: 
Auswirkungen von HSO 
zu erheben 
3 Methoden:  
Download-Analyse, 
Online-Umfrage und 
Umfeldanalyse 
HSO Berichte wurden 
6,671 Mal 
heruntergeladen 
71% der Befragten 
verwenden HSO 
Berichte 
LBI-HTA LBI-HTA  
publiziert HSO Berichte 
fru¨h – im Schnitt 4 
Monate nach EMA 
Zulassung 
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Umfeldanalyse zeigte auch, dass das LBI-HTA mit seinen Bewertungen von 
onkologischen Medikamenten eines der ersten Institute ist - im Durch-
schnitt innerhalb von 4 Monaten nach der Zulassung durch die European 
Medicines Agency. Dennoch bleiben einige Fragen unbeantwortet: beein-
flussen HSO Berichte Entscheidungen; warum verwenden nur wenige Kli-
nikerInnen diese Berichte?  
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1 Introduction  
1.1 Background Horizon Scanning Systems 
Several countries (e.g. UK, Norway, Sweden, Belgium, Canada and Austra-
lia) have established so called ‘Horizon Scanning Systems’ (HSS), ‘Early 
Warning Systems’ or ‘Early Awareness and Alert Systems’ (EAAS) to sup-
port decision-makers with information about new or emerging health tech-
nologies which might have an important impact (i.e. financial or clinical) for 
the health care system prior to their wide-spread adoption and introduction 
into national health care systems [1].   
New health technologies raise a lot of questions concerning managed intro-
duction, financial burdens, organisational requirements and clinical practice 
changes. Consequently, HSS units are often part of an HTA agency since 
HSS can be seen as the first stage of a comprehensive HTA process [2]. The 
main difference to regular HTA reports is that HSSs focus on technologies 
early in their life-cycle, whereas HTA concentrates on the assessment of al-
ready established health technologies.  
The difference between new technologies and emerging technologies is that 
the former ones are in the phase of adoption, they have been available for 
clinical use only for a short time and are at launch or at early post marketing 
stages. In contrast, an emerging technology is defined as not yet adopted. In 
the case of pharmaceuticals, this would correspond to phase II or phase III 
of clinical development or to pre-launch.  
EAASs aim to identify, filter and prioritise new and emerging health tech-
nologies, to assess or predict their impact on health, costs, society and the 
health care system and to inform decision makers [3].  
Six main stages are involved in early awareness and alert systems [3]:  
1. Horizon Scanning/Identification 
2. Filtration (identifying new and emerging technologies that are rele-
vant for the individual EAAS) 
3. Prioritisation (deciding on technologies in which further resources 
for investigation are to be invested) 
4. Assessment (presenting information on anticipated impact on 
health care and health services) 
5. Dissemination (ensure that the information produced is reaching 
the correct audience in a timely fashion) 
6. Updating information. 
HSS to support decision-
making processes about 
new and emerging 
technologies 
most HSS units are part 
of an HTA agency 
6 steps of EAAS:  
scanning/ identification, 
filtration,  
prioritisation,  
assessment,  
dissemination and 
updating the 
information 
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1.2 Background Horizon Scanning in 
Oncology 
Around 38,000 people are diagnosed with cancer in Austria each year, with 
men being affected slightly more frequently than women [4]. After cardio-
vascular diseases, cancer is the second most common cause of death in both 
sexes. In view of the fact that these diseases occur primarily in older people, 
the importance of cancer incidences will continue to grow due to the increas-
ing age of the population [4]. 
Due to rising expenditures for cancer therapies, an instrument was needed 
in Austria to facilitate the evidence-based use of new anticancer drugs and to 
pre-estimate their financial implications [5]. Especially the so-called ‘tar-
geted therapies’ such as monoclonal antibodies or tyrosine kinase-inhibitors 
(‘small molecules’) have stressed hospital budgets. Therefore, the LBI-HTA 
implemented ‘Horizon Scanning in Oncology’ (HSO), a HSS specifically 
targeted on oncology drugs. After a first concept was developed and piloted 
from July 2007 until May 2008, the HSO program was implemented as stan-
dard practice at the LBI-HTA in October 2009.  
The objective of HSO is to provide information about new and emerging 
anti-cancer drugs with a likely therapeutic and/or financial impact on Aus-
trian hospitals (i.e.hospital management, drug commissions, pharmacists) 
and funding agencies in order to support budget planning and rational deci-
sion making. By scanning information sources on a regular basis, by identi-
fying new and emerging drugs and by prioritising these new drugs through 
an expert panel, relevant drugs are selected for assessments. Since late 2009 
(until 1st March 2012; cut-off date for this analysis), the LBI-HTA has pub-
lished 24 reports and 3 updates. Besides entries to LBI-HTA’s homepage, 
these reports are disseminated by three different means: 
 email-alerts on newly published reports which are sent to relevant de-
cision-makers in Austrian hospitals, 
 notifications in the LBI-HTA’s monthly newsletter, 
 entries to the EuroScan database, the database of a collaborative net-
work of HSS agencies. 
 
38,000 are diagnosed 
with cancer in Austria 
each year 
HSO was implemented 
as standard practice in 
October 2009 
LBI-HTA published 27 
reports on new anti-
cancer drugs since late 
2009 
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2 Objectives and research question 
Since considerable resources are dedicated to the HSO project and since an-
ti-cancer drugs are on the agenda of many scientific institutes worldwide, 
two main questions arose: 
1. What is the impact of the HSO in Austria? 
2. Is there overlap/room for international collaboration with other in-
stitutes involved in assessing anti-cancer drugs?  
These research questions were operationalized by further breaking them 
down as follows: 
Ad 1.)  
 What is the usage of the HSO reports (download and access rates)? 
 Which HSO reports have been downloaded frequently and which ones 
rarely? 
 Who are the readers of HSO decision support documents? 
 Which professional groups use HSO reports? 
 Are HSO reports used for decision-making? 
 What types of decisions are based on HSO reports? 
 Are there any improvements to be made with the reports itself, dis-
semination and/or marketing strategies? 
Ad 2.)  
 Which and how many other institutes assess anti-cancer therapies? 
 At what point in time are these assessments published in comparison 
to the publication date of the HSO? 
 What is the scope of these reports? 
 Is there any need to adjust ways of identification/prioritization or the 
compilation of assessment reports in order to reduce redundancies 
with other HTA institutes? 
 
impact in Austria? 
overlap and room for 
collaboration? 
usage of the reports? 
who are the readers? 
applicability of reports? 
who else assesses  
anti-cancer drugs? 
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3 Methods 
3.1 Impact evaluation 
Although the importance of HTA research has increased over the last few 
years and its scientific methods are implemented in many countries, there is 
hardly any evaluation of HTA-based results. Despite existing impact evalua-
tion research, no model has been generally accepted. Furthermore, it is still 
unclear how to define impact. For example, do people have to be aware of 
the content of an HTA report only or need recommendations resting on 
HTA reports be actually implemented [6]? 
This impact evaluation of the HSO program is based on a framework sug-
gested by Schumacher and Zechmeister [7]. This framework contains in-
struments and potential evaluation designs for measuring the impact of 
HTA products in Austria. According to this report and based on Gerhardus 
et al. [8] seven hierarchically structured dimensions of impact can be differ-
entiated: 
1. Awareness: Affected people know that HTA is available as support 
for decision-making. 
2. Acceptance: HTA recommendation is considered as a valid and ac-
ceptable decision-support. 
3. Policy process: HTA is explicitly used within decision-
making/development processes. 
4. Policy decision: A decision is clearly influenced by an HTA result 
or recommendation. 
5. Practice: The decision has been put into practice. 
6. Final outcomes: Changes in practice become visible through bene-
fits in health or budget cutbacks (real objective of HTA). 
7. Enlightenment: HTA results are not put into clinical practice di-
rectly, but decision-making processes as well as communication be-
tween researchers and the public are facilitated with available HTA 
reports.  
The report by Schumacher and Zechmeister [7] also highlights that impact 
of HTA is multidimensional, and can also be direct (i.e. HTA reports are 
considered and/or recommendations are accepted) or indirect (=unintended 
effects, i.e. opinion can induce opposing views). Furthermore, several levels 
where impact can arise can be distinguished: the macro-, meso- or micro-
level. The micro-level includes individuals, such as scientists, patients, doc-
tors or citizens. The meso-level comprises institutions and other groups of 
people such as hospitals, insurance companies, expert panels or professional 
organizations. The macro-level, on the other hand, consists of players such 
as political institutions (federations and states), the therein located govern-
ing bodies (i.e. federal commission of health, federal health care funds, and 
committees) and other players (media and industry) [7].  However, even 
though impact is not a measure for the success of a work program of an 
HTA-institute per-se, evaluation of impact is an important aspect for the fu-
ture orientation of HTA research [7]. 
no generally accepted 
model of impact 
evaluation 
a framework was 
developed by LBI-HTA 
to evaluate impact of 
HTA reports 
7 levels of impact 
impact of HTA is 
multidimensional 
impact evaluation  
gives orientation 
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The applications of at least two evaluation methods – a combination of qual-
itative and quantitative methods – are recommended to validate the results  
[7]. For the evaluation of the HSO program, the following methods were 
chosen:  
1. a download analysis  
2. an online survey.  
Table 3.1-1 shows the 7 levels according to which impact can be measured as 
well as corresponding methods for evaluation. Also, the levels used for 
measuring the impact of HSO and the methods chosen for this evaluation 
are displayed.  
Table 3.1-1: Adapted framework for measuring impact of HSO in Austria  
Impact/  
objectives 
Indicators Pool of methods for 
measuring impact 
Methods used for HSO 
evaluation 
awareness downloads of project reports Download analysis 
Online  survey 
acceptance consulted as decision support Online   survey 
policy  
process 
HTA research is considered Online  survey 
policy  
decision 
HTA is cited as reason for  
decisions 
Online  survey 
practice amount (newer/other)  
devices/technologies 
-  
final outcomes health benefits, budget cutbacks -  
enlightenment transportation of topics in media, 
changes in journalism, establish-
ment of new research activities, 
participation of HTA researchers 
in governing bodies 
 
 
 
 
 
data analysis, document 
analysis, questionnaire, 
interviews, focus group 
interviews, cost analysis, 
discourse analysis 
-  
Methods 
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3.1.1 Download analysis 
Like most other HTA-institutes the LBI-HTA provides free long-term access 
to all its publications (all documents are accessible via the website: 
http://eprints.hta.lbg.ac.at). In total, 27 HSO-reports were published be-
tween August 2009 and March 2012: 24 decision support documents and 3 
updates. In the first year (2009), 7 HSO reports were published and up-
loaded to the website. In 2010, further 7 decision support documents were 
added to the website, another 7 reports and 3  Updates in 2011. In the first 3 
months of 2012, 3 further reports were uploaded to the website.  
Access to the HSO reports 
The homepage of the LBI-HTA offers a search function in its repository al-
lowing to search by type of publication, subject, author/editor, institution 
and/or year. By clicking on a publication title a publication window  dis-
playing  abstract, key words and subject pops up. A PDF file of the publica-
tion can be downloaded by following the provided link. 
The site-views (i.e. how often the websites were viewed) and the download 
rates (i.e. how often the PDF files were downloaded from the website) were 
generated for all decision support documents published since the implemen-
tation of HSO in late 2009 until 1st of March 2012. To check the plausibility 
of the download rates, the amount of total downloads were compared with 
the number of the site-views which is expected to be higher or equivalent 
because, usually, the websites have to be accessed before the reports can be 
downloaded.  
However, reports can also be accessed directly, if, for example, the PDF link 
is sent by email, as is the case with e-mail notifications. These email-alerts 
on newly available HSO documents are sent to decision-makers in Austrian 
hospitals and include a direct link to the publication. Another possibility to 
access reports is via the monthly HTA-newsletter of the LBI-HTA which is 
sent to approx. 900 subscribers, mostly from Austria and Germany. LBI-
HTA’s newsletters were downloaded 13,907 times in 2009, increasing to 
13,937 downloads in 2010 and to 14,110 in 2011. This newsletter briefly re-
ports on several health technologies assessed either by LBI-HTA or by other 
HTA-institutes. Newly published decision support documents about anti-
cancer drugs are also reported in these HTA-newsletters but irregularly.   
HSO reports can also be found by searching in the repository of the insti-
tute’s website, or by a free hand search on the internet or other HTA or pub-
lic health-related databases. There are several link exchangers or listings 
within HTA networks (i.e. EuroScan [9], EUnetHTA [10], INAHTA [11]). 
Additionally, there are hyperlinks to the reports on the Austrian Ministry of 
Health website. Finally, the HSO program is referenced in various printed 
and online publications. For example, AKDAE [12] cited LBI-HTA’s HSO 
reports in its advisory opinion on Cabazitaxel and Eribulin.  
Therefore, site-views/download rates of the reports are not only the result of 
email-alerts or the distribution of LBI-HTA’s newsletters but are also linked 
to various other websites and external databases (i.e. CRD database [13], 
EUnetHTA database [10], EuroScan database [9]). 
HSO reports are 
available online 
24 decision support 
documents and  
3 updated reports 
general access of 
scientific reports 
comparison of site- 
views rate and 
download rate 
accessing HSO reports 
by email-alerts and 
notices in the HTA-
newsletter 
active search on LBI-
HTAs website, in 
Google, other databases 
or printed/online 
publications 
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Aim of the download analysis 
The aim of the download analysis is to evaluate the impact of the LBI-HTA 
HSO reports with regards to the amount of website views and publication 
download rates. The site-views and download rate which are extracted from 
the institutes website show how often these reports have been viewed and 
downloaded by the general public. 
Questions 
The download analysis should answer the following questions:  
 How often are decision support documents viewed and downloaded 
from the website in total and on average? 
 Did the amount/rate of downloads change over time? 
 Which documents have been downloaded frequently and which ones 
rarely? 
 Are there any links between active notifications (HTA-newsletters, e-
mails to HSO mailing list) and download rates? 
 Are there any explanations for the frequently/rarely demanded 
downloads of certain reports? 
Methods 
By using AWStats (Advanced Web Statistics 6.9), the amount of site-views 
(how often the websites were viewed) and the amount of downloads (how of-
ten the PDF files were downloaded) were generated. Only the site-
views/downloads performed by the public are counted, whereas the clicks 
performed by staff members are excluded. However, it was not possible to 
eliminate external multiple downloads (i.e. one person downloading an HSO 
report more than once) and therefore all external clicks were counted. The 
total number of downloads, PDF average monthly download rate and the to-
tal monthly average were calculated. 
The total number of downloads is the number of all downloads from the first 
month of the publications’ upload to the website. However, a proper com-
parison between reports might be confounded, since some documents have 
been online longer than others.  
To ensure comparability between the documents the variable ‘PDF average 
monthly download rate’ of all publications was calculated. This variable is 
calculated by the total number of downloads within a year divided by the 
months the publications were effectively online.  
For example, the report ‘Bendamustin’ (DSD HSO Nr 10) which was pub-
lished online in July 2010 was downloaded 261 times in 2010. The monthly 
average was calculated as follows: 
7/2010 until 12/2010 = 6 months online in total in 2010 
261/6 = 43.5 
The average monthly download rate of ‘Bendamustin’ was therefore 43.5.  
In addition to this average monthly download rate, the total monthly average 
was calculated. This was performed by  calculating of all downloads divided 
by the total number of months being published online. For example the 
how often are decision 
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downloaded? 
questions addressed 
within the download 
analysis 
statistical evaluation of 
website-views and 
download rate 
total number of 
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average downloads 
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same report ‘Bendamustin’ (DSD HSO Nr 10) with total downloads of 914 
the calculation is performed by:  
07/2010 until 02/2012 = 20 months online in total 
914/20 = 45.7. 
The document was downloaded 45.7 times in total in a month. 
Download rates of individual HSO-reports might have been influenced by 
an increasing publicity of the HSO program over the years, by the 
time/month of publication (e.g. closeness to the annual prospective drug-
budgeting in hospitals or reimbursement decisions) etc. However, one can 
only speculate upon those potential influences, since a more thorough analy-
sis seems to be impossible. 
3.1.2 Online survey 
A questionnaire is the most commonly used tool to evaluate the impact of 
HTA results [7]. Information about attitude and knowledge about HTA re-
ports are assessed. As an indicator for knowledge the item ‘Knowing, that 
HSO reports exist’ were used (see Appendix for the questionnaire). In an 
open section, respondents had the possibility to express their personal opin-
ion and to make suggestions for improvements [7]. 
Aim of the online survey 
By asking recipients of the HSO email-alerts, this survey is conducted to as-
sess awareness about the reports, overall satisfaction with the quality and 
content. Applicability and usefulness of the reports were of particular inter-
est.  
Questions 
The online survey should answer the following questions: 
 How many email-alert recipients are aware of the HSO reports? 
 Which professional groups are reading the HSO decision support 
documents? 
 For which type of decisions are the reports used? 
 Are the reports used to support decisions about implementing new 
drugs/reimbursing medical expenses for new drugs? 
 What other information on new anti-cancer drugs are read to support 
in decision making? 
 How are readers of HSO reports informed about newly published re-
ports? 
 How well are HSO reports perceived in performing in terms of quality 
(relevance, balanced information etc.)? 
 How satisfied are HSO report readers with the content of the DSD 
documents? 
 What are the suggestions for changes and improvements? 
additional influences: 
closeness to 
reimbursement 
decisions  
about attitude  
and knowledge  
aim of the online survey 
was to question target 
audience 
…the underlying 
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Methods 
When new HSO reports are published on the LBI-HTA’s website, email-
alerts are sent to relevant Austrian decision makers. The recipients of these 
alerts were invited to participate in the survey. The online survey was cre-
ated and implemented with the software provided by Enuvo on 
www.umfrageonline.com. Due to the fact that all survey recipients were ei-
ther from Austria or from Germany, the survey was in German. Participa-
tion in the survey was anonymous and voluntary. 
Structure of the online survey 
In general, the survey consisted of questions about overall satisfaction with 
the quality and content of the reports, applicability and usability of the re-
ports. The first part of the survey asked the participants about their profes-
sion and job location. In the second part questions posed intended to assess 
if participants were involved in decision-making processes (applying new 
anti-cancer drugs and/or refunding expenses for new anti-cancer drugs). The 
participants were asked to rate the quality and their satisfaction with the 
content of the reports. Further, it was of interest to assess which sources 
were used for decisions on administering/refunding new oncology drugs and 
if the drugs assessed by LBI-HTA were relevant for the readers. The partici-
pants were also asked about the way they received information about new 
HSO reports. Finally, the participants were invited to give feedback and to 
make suggestions for improvements on future reports. The questions of the 
online survey can be found in Table 8.1-1 (see Appendix). 
3.2 Environmental analysis 
Since anti-cancer drugs are subject of evaluations in many institutes, there 
might be a considerable overlap in topics assessed. The point of time in the 
life-cycle when these anti-cancer drugs are assessed (i.e. in relation to the li-
censing decisions of the European Medicines Agency) as well as the content 
of the reports are therefore of interest to identify redundancies as well as po-
tential ways for collaboration.  
Aim of the environmental analysis 
The aim of the environmental analysis is to identify other HTA agencies 
performing (early) assessments of anti-cancer drugs. An analysis of the im-
mediate environment helps to identify relevant HTA institutions or any 
other relevant organization for possible future collaborations. In addition to 
that, the environmental analysis might help to sharpen the specific profile of 
the HSO program.  
Questions  
The environment analysis should answer the following questions: 
 Who else/ which other HTA-agencies conduct (early) assessments on 
anti-cancer drugs? 
 At what point in time of a life-cycle do other HTA-agencies conduct 
their assessments? 
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the quality and content 
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 Which type of content is provided within other drug assessment re-
ports? 
 What is the timing of publication of the LBI-HTA in comparison to 
other HTA organisations? 
 In comparison to licensing decisions by the European Medicines 
Agency, when are HSO reports published? 
 Do LBI-HTA HSO reports have a unique standing concerning close-
ness to time of approval? 
Methods  
To identify and thus to get a comprehensive overview about other HTA in-
stitutions performing (early) assessments of new and emerging anti-cancer 
drugs, two research methods were used.  
1. The first strategy was to search in scientific databases for the 24 
anti-cancer drugs which had been assessed by LBI-HTA since late 
2009. In March 2012, the following databases were searched for 
these anti-cancer drugs: CRD HTA database, INAHTA database, 
EuroScan database and EUnetHTA POP database (only accessible 
for members). This strategy identifies other HTA institutes having 
published assessments on the specified drugs and gives an overview 
on their products. A brief description of the databases used is pro-
vided in the Appendix. 
2. To identify other HTA institutions possibly performing assess-
ments of anti-cancer drugs, which might not be listed in one of the 
databases, the second method was to screen the websites from over-
arching HTA network organizations (INAHTA; EuroScan, 
EUnetHTA and HTAi). The member lists of these organizsations 
were pulled together and each institute’s website was screened for 
publications about anti-cancer drugs. The method consisted of 
searching (1) for relevant material in the publications section of 
websites if applicable, (2) for the term ‘cancer’ and (3) for drugs 
(e.g. Everolimus, Bendamustin, Nilotinib) already assessed by the 
LBI-HTA.  
Inclusion criteria were reports published in English and/or German and 
publicly available documents. 
Method 1: Search in databases 
EUnetHTA POP database 
The search in the EUnetHTA POP database was performed by typing in the 
24 anti-cancer drugs of LBI-HTA in addition to the MeSH-Term ‘neo-
plasms’. The results showed that there were 214 projects in the database: 3 of 
them were abandoned, 133 projects were ongoing, 58 were planned and 20 
project reports were finalised and published. After reviewing the finished 
projects 11 reports were related to anti-cancer drugs. The reports were pub-
lished by IQWiG (Cabazitaxel, Eribulin), NICE (Imatinib, Nilotinib, 
Cetuximab, Rituximab, Panitumumab) and AHTAPol (Gefinitib).  
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INAHTA database 
The search for publications in the INAHTA publication section was per-
formed by searching for the disease category ‘neoplasms’. There were 208 
publications listed but no assessment reports about new anti-cancer drugs 
were detected, because INAHTA is linked to the CRD database. 
EuroScan 
The EuroScan database was searched for the 24 anti-cancer drugs assessed 
by the LBI-HTA in addition to the MeSH term ‘Technology-type: drugs’ and 
‘Specialty: Oncology & radiotherapy’.  
Searching for the MeSH terms ‘drugs’, ‘hematology & blood products’ and 
‘oncology & radiotherapy’ showed that there were 123 anti-cancer drugs re-
lated entries (the 24 LBI-HTA reports excluded). The NHSC had the most 
entries with 121 reports, IHSP had 20 and DMTP one. Searching for the 24 
drugs showed that there were entries by NHSC about nearly all 24 drugs as-
sessed by LBI-HTA except for Bendamustin, S-1 and Vemurafenib. CADTH 
had a report published on Gefitinib. Entries from DMTP were found for 
Azacitidine, Gefitinib, Lapatinib, Ipilimumab and Erlotinib but no reports 
were available online or were found after further search on the agencies’ 
website respectively. 
CRD HTA database 
Again, this database was searched for the 24 drugs assessed by LBI-HTA. 
Most of the HSO assessment reports about anti-cancer drugs were found in 
the CRD database. 
Method 2: Screening of HTA institutes websites 
The members list extracted from the overarching HTA networking organisa-
tions (INAHTA; EuroScan, EUnetHTA and HTAi) consisted of 106 organi-
sations in total. The screening of these HTA institutes’ websites showed that 
there were in total only 10 institutes/websites with publications about anti-
cancer drugs. Out of 10 institutes 8 publish their reports in English and 2 
institutes published the reports in German. There were several organisations 
listed which were not an HTA institute. Also governmental organisations, 
drug commissions, health services, medicines agencies, ministry of health 
departments and universities are listed members of these overarching HTA 
networks. Nevertheless, all websites were screened for available assessment 
reports on anti-cancer drugs. The inclusion criteria were: assessments of 
anti-cancer drugs, publicly available and publications written in English 
and/or German.  
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4 Results 
4.1 Impact evaluation 
4.1.1 Download analysis 
Overview on downloads 
In general, HSO decision support documents of new or emerging anti-cancer 
drugs have been viewed in total 13,737 times and downloaded 6,671 times 
between October 2009 and February 2012. The reports were downloaded be-
tween 7 and 51 times on average per month. An overview about the 
download and site-views rate of all reports is provided in Table 4.1-1. 
This table also shows the monthly average download rate of all reports per 
year. In the first year of publication, reports were downloaded on average 11 
times per month. After an increase to 23 downloads on average per month in 
2010, downloads remained constant in 2011. In the first 2 months of 2012, 
the rate increased to 42 downloads on average per month. The total 
downloads on average per month is 25. As Table 4.1-1 shows there is a trend 
towards increased downloads of newly published reports over time. 
Table 4.1-1: Downloads of all reports on average per month 
Year Number of reports online Average of monthly  
downloads of all reports 
2009 7 11.1 
2010 14 22.5 
2011 21 22.8 
2012 24 42.3 
 
Reports were downloaded at minimum 7 times on average in a month (Ibri-
tumomab: 12/2009) at the beginning of the HSO-program and at maximum 
51 times on average in a month (Everolimus – pancreatic cancer: 12/2011, 
but it had been available only for 2 months) (see Table 4.1-2). The report 
most often downloaded was Bendamustin (7/2010), which had been pub-
lished 4 months after the refusal of the EMA (average per month 46, abso-
lute downloads: 914). Plerixafor (3/2010) was downloaded 2nd most often in 
absolute numbers (419 times), but on average only 18 times per month. 
Other reports which had been downloaded more than 20 times on average 
per month and at least 200 times (absolute) were: Ipilimumab (12/2010) – 
25/ 349 (per month/ absolute), Cabazitaxel (2/2011) – 24/ 516, Dasatinib 
(2/2011) – 22/241 and Eribulin (6/2011) 31/ 252. 
Other reports which had been downloaded quite often (more than 200 times) 
in absolute terms, but more rarely on average were:  Azacitidine (8/2009) – 
on average 12/ absolute 342, Cetuximab (9/2009) – 11/ 320, Everolimus 
(9/2009) – 13/381, Rituximab (10/2009) – 10/ 258, Gefitinib (12/2009) – 12/ 
305, Trabectedin (11/2009) 13/334, Lapatinib (5/2010) – 14/272,  Panitu-
13,737 website-views and 
6,671 downloads since 
October 2009 
total downloads on 
average per month is 25  
reports are downloaded 
at minimum 7 and at 
maximum 51 times on 
average in a month 
Bendamustin: 914 times 
Plerixafor: 419 times 
more than 20 times 
average p.m. and at 
least 200 times:  
4 reports  
at least 200 times 
downloads: 
11 reports 
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mumab (6/2010) – 18/353, Trastuzumab (5/2010) – 18/ 357, Pazopanib 
(10/2010) – 17/272 and Nilotinib (1/2011) – 19/286. 
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Table 4.1-2: Download analysis of HSO reports 
Report No./ 
Generic name of the drug/ 
indication 
Date of  
publication Link 
Total web-
site views 
PDF total 
downloads
PDF average  
downloads per 
month 
Download 
in 2009 
Download 
in 2010 
Download 
in 2011 
Download  
in 2012 
1/ Azacitidine/ Myelodys-
plastic syndrome 08/2009 http://eprints.hta.lbg.ac.at/852/ 744 342 11.79 116 77 129 20 
2/ Cetuximab/ EGFR-
expressing NSCLC 09/2009 http://eprints.hta.lbg.ac.at/856/ 915 320 11.03 108 48 141 23 
3/ Everolimus/ 2nd –line 
therapy for ad-
vanced/metastatic kidney 
cancer 
09/2009 http://eprints.hta.lbg.ac.at/857/ 1752 381 13.14 114 89 146 32 
4/ Rituximab/ 1st- and 2nd- 
line chronic lymphocytic 
leukemia 
10/2009 http://eprints.hta.lbg.ac.at/860 1016 258 9.56 64 50 120 24 
5/ Ibritumomab tiuxetan/ 
Consolidation therapy for 
follicular lymphoma 
12/2009 http://eprints.hta.lbg.ac.at/861 345 185 6.85 45 33 90 17 
6/ Gefitinib/ 1st-line NSCLC 12/2009 http://eprints.hta.lbg.ac.at/868 852 305 12.2 - 99 175 31 
7/ Trabectedin/ 2nd-line re-
current platinum-sensitive 
ovarian cancer 
11/2009 http://eprints.hta.lbg.ac.at/869 1226 334 13.36 - 135 175 24 
8/ Plerixafor/ Autologous 
stem cell transplantation in 
patients with lymphoma 
and multiple myeloma 
03/2010 http://eprints.hta.lbg.ac.at/878 590 419 18.22 - 204 182 33 
9/ Lapatinib/ 1st-line ad-
vanced/metastatic breast 
cancer 
05/2010 http://eprints.hta.lbg.ac.at/882/ 381 272 13.6 - 123 137 12 
10/ Bendamustin/ Indolent 
non-Hodgkin’s lymphoma 
(NHL), chronic lympho-
cytic leukaemia (CLL) and 
multiple myeloma (MM) 
07/2010 http://eprints.hta.lbg.ac.at/884/ 1732 914 45.7 - 261 543 110 
11/ Panitumumab/ 1st-line 
treatment of metastatic co-
lorectal cancer 
06/2010 http://eprints.hta.lbg.ac.at/880/ 470 353 17.65 - 107 215 31 
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12/ Trastuzumab/ 1st-line 
advanced gastric cancer 05/2010 http://eprints.hta.lbg.ac.at/881/ 456 357 17.85 - 125 206 26 
13/ Pazopanib/ 1st line ther-
apy of locally advanced 
and/or metastatic renal cell 
carcinoma 
10/2010 http://eprints.hta.lbg.ac.at/902 398 272 16.82 - 64 241 31 
14/ Ipilimumab/ Pre-treated 
patients with ad-
vanced/metastatic mela-
noma 
12/2010 http://eprints.hta.lbg.ac.at/905 448 349 24.93 - - 292 57 
15/ Nilotinib/ 1st-line treat-
ment of Philadelphia chro-
mosome positive chronic 
myeloid leukaemia in the 
chronic phase 
01/2011 http://eprints.hta.lbg.ac.at/906 336 286 19.43 - - 197 25 
16/ Cabazitaxel/ 2nd line 
chemotherapy for castra-
tion-resistant metastatic 
prostate cancer 
02/2011 http://eprints.hta.lbg.ac.at/911/ 516 262 23.82 - - 231 31 
17/ Dasatinib/ 1st-line 
treatment of Philadelphia-
chromosome positive 
chronic myeloid leukaemia 
in the chronic phase 
02/2011 http://eprints.hta.lbg.ac.at/910/ 398 241 21.91 - - 194 47 
18/ Eribulin/ 3rd- or  late-line 
mono-therapy for ad-
vanced/metastatic breast 
cancer 
06/2011 http://eprints.hta.lbg.ac.at/927 304 252 31.5 - - 204 48 
19/ S-1/ 1st-line therapy for 
patients with advanced 
NSCLC 
07/2011 http://eprints.hta.lbg.ac.at/931 121 95 15.83 - - 62 33 
20/ Abiraterone acetate/ 
2nd-line therapy for the 
treatment of metastatic 
castration-resistant pros-
tate cancer after docetaxel 
therapy 
11/2011 http://eprints.hta.lbg.ac.at/938 217 139 46.33 - - 16 123 
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21/ Axitinib/ 2nd- line treat-
ment of metastatic renal 
cell carcinoma 
01/2012 http://eprints.hta.lbg.ac.at/945 37 37 37 - - - 37 
22/ Erlotinib/ 1st- line 
treatment of patients with 
locally advanced or metas-
tatic NSCLC with EGFR ac-
tivating mutations 
01/2012 http://eprints.hta.lbg.ac.at/941 40 47 47 - - - 47 
23/ Vemurafenib/ for pa-
tients with BRAF V600E 
mutation positive ad-
vanced/metastatic mela-
noma 
01/2012 http://eprints.hta.lbg.ac.at/940 84 71 36 - - - 71 
24/ Everolimus/  
unresectable or metastatic 
neuroendocrine tumours of 
pancreatic origin 
 
12/2011 http://eprints.hta.lbg.ac.at/942 54 51 51 - - - 51 
HSO UPDATES          
25/ Rituximab update 10/2011 http://eprints.hta.lbg.ac.at/937 135 52 26 - - 19 33 
26/ Gefitinib update 08/2011 http://eprints.hta.lbg.ac.at/935/ 67 39 9.75 - - 24 15 
27/ Panitumumab update 10/2011 http://eprints.hta.lbg.ac.at/936/ 73 38 9.5 - - 27 11 
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Timeline of report downloads 
The evaluation of the download rates over time showed that downloads were, 
in general, highest in the first after publication and were slowly decreasing 
(see Figure 4.1-1) as time progressed. 
Figure 4.1-1: Timeline of report downloads of HSO-DSD 1-8 
Influence of email notifications and HTA newsletters articles 
on download rates 
As mentioned above, besides notifications on the LBI-HTA’s homepage, two 
active methods for disseminating the findings of HSO reports are used. 
These are articles in the LBI-HTA’s newsletter and active email-
notifications to hospital directors, hospital pharmacists as well as to mem-
bers of drug commissions. It is of interest, if there is any timely association 
between these dissemination methods and download rates. The timeline of 
these different notification methods is also displayed in Figure 4.1-1, Figure 
4.1-2 and Figure 4.1-3. 
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Table 4.1-3: Overview on publication dates and temporal relationship to active dissemination 
methods for HSO reports 
Drug  Publication date  
on LBI homepage 
Email  
notification date 
HTA newsletter  
date 
Axitinib February 2012 February 2012 - 
Everolimus February 2012 February 2012 - 
Erlotinib February 2012 February 2012 - 
Vemurafenib January 2012 - - 
Abiraterone acetate December 2011 December 2011 - 
Rituximab December 2011 December 2011 - 
Panitumumab November 2011 December 2011 - 
Gefitinib November 2011 November 2011 November 2011 
S-1 September 2011 November 2011 September 2011 
Eribulin July 2011 July 2011 - 
Cabazitaxel April 2011 April 2011 - 
Dasatinib April 2011 April 2011 - 
Ipilimumab January 2011 January 2011 February 2011 
Nilotinib January 2011 January 2011 February 2011 
Pazopanib October 2010 October 2010 - 
Lapatinib ditosylate July 2010 July 2010 September 2010 
Bendamustin July 2010 July 2010 September 2010 
Panitumumab July 2010 July 2010 September 2010 
Trastuzumab July 2010 July 2010 September 2010 
Plerixafor April 2010 - - 
Gefitinib January 2010 February 2010 - 
Trabectedin  January 2010 February 2010 - 
Azacitidine October 2009 November 2011 - 
Cetuximab October 2009 November 2011 - 
Everolimus October 2009 November 2011 - 
Rituximab October 2009 November 2011 - 
Ibritumomab tiuxetan October 2009 November 2011 - 
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Figure 4.1-2 shows an increase in downloads of the anti-cancer drugs Ben-
damustin, Lapatinib, Panitumumab, and Trastuzumab in September 2010. 
In this month, the HTA newsletter no. 90 of LBI-HTA was published, intro-
ducing these 4 new anti-cancer therapies.  
Figure 4.1-2: Timeline of report downloads of HSO-DSD 9-12 
Figure 4.1-3 shows that there was also an increase in the download rate of 
the reports about Ipilimumab and Nilotinib in early 2011. During this time, 
the LBI-HTA published its 94th newsletter including articles on these anti-
cancer drugs. An email-alert about the newly published report of Pazopanib 
was sent in October 2010 and another about Nilotinib and Ipilimumab in 
January 2011. Dasatanib and Cabazitaxel were announced in an email-alert 
in April 2011. 
Figure 4.1-3: Timeline of report downloads of HSO-DSD 13-17 
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4.1.2 Online survey 
After a pre-test, the online survey was finally sent out in late March 2012. 
Overall, the survey was accessible for 3 weeks. On 28th of March 2012 an in-
vitation to participate in the online survey was sent to all email-alert recipi-
ents on new HSO reports (n=130). From 130 invitations sent, 4 failure no-
tices returned. These invitees were excluded from the survey. Due to the fact 
that the participation in the survey was anonymous, reminders were sent to 
all recipients despite participants having already completed the survey. 
17.46% (n=22) of the invitees completed the online survey within the first 
two days. Two reminders were sent, the last on 16th of April 2012, resulting 
in a final response rate of 29 % (n=36).  
Socio-demographic data 
Questions on socio-demographic data comprised profession and job location. 
All participants answered these questions. Figure 4.1-4 shows the distribu-
tions of the professions. Out of 36 participants 3 interviewees stated to have 
2 of the listed job functions. These were 3 pharmacists being also a member 
of the drug commission.  
Figure 4.1-4: Professions of the interviewees 
94% of the survey participants stated to work in Austria (Vienna (17%), 
Lower Austria (17%), Upper Austria (17%), Styria (11%), Tyrol (11%), 
Carinthia (9%), Salzburg (6%), Burgenland (3%) and Vorarlberg (3%)). The 
remaining 6% were from Germany.  
Involvement in decision-making 
The question ‘Are you involved in decision making on the usage and/or re-
imbursement of oncology drugs?’ was answered also by all 36 participants. 
72% of the interviewees (n=36) said that they were either involved in deci-
sion making on the usage and/or reimbursement of oncology drugs.  
130 invitations to 
participate in the online 
survey were sent in 
March 2012 
the response rate 
increased after 3 weeks 
to 28.57%. 
49% of the participants 
were pharmacists 
72% are involved in 
decision making 
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Other information sources used 
As Figure 4.1-5 shows, authorisation papers (28%), primary studies of drugs 
(25%), documents from the pharmaceutical industry (25%), decision sup-
port documents provided by LBI-HTA (21%) and others (6%) were used by 
the interviewees to make decisions about the usage and/or reimbursements 
of oncology drugs. Other sources specified were reports from organisations 
such as HAS, CVZ, IQWIG or from NICE. Also listings of organisations re-
lating to haematology/cancer such as American Society of Hematology, Na-
tional Comprehensive Cancer Network or European Hematology Associa-
tion were mentioned as information sources. 
Figure 4.1-5: Information sources used for decision-making processes 
Awareness about Horizon Scanning in Oncology 
The mandatory question ‘Do you know the work program ‘Early assessment 
of anti-cancer drugs’ of the LBI-HTA?’ was completed by 33 survey partici-
pants, but only 58% answered that they knew HSO. 
Participants stating that they did not know HSO were then asked in a subse-
quent question if they would read HSO reports – 82% responded that they 
would do so. 
Satisfaction with HSO reports 
44% of the participants declared to be ‘completely satisfied’ and 50% to be 
‘satisfied’ with the structure of the reports. Only 6% stated to be ‘somewhat 
dissatisfied’. The breadth of the reports was ‘completely satisfying’ for 59% 
of the participants and ‘satisfying’ for 35%. Only 6% of the readers stated to 
be ‘fairly satisfied’. 50% of the readers were ‘completely satisfied’ and an-
other 50% were ‘satisfied’ with content and quality of the reports.  
With the timing of the publication, 47% stated to be ‘completely satisfied’, 
35% to be ‘satisfied’ and 18% to be ‘fairly satisfied’. The notification type 
about new reports (by email-alerts) was ‘completely satisfying’ for 56% of 
the readers, ‘satisfying’ for 39% whereas 6% were not able to answer this 
question.  
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Table 4.1-4: Satisfaction with the reports 
 completely  
satisfied 
satisfied fairly  
satisfied 
somewhat 
dissatisfied 
very  
dissatisfied 
not able  
to judge 
structure of the  
reports 
44% 50% - 6% - - 
breadth of the reports 59% 35% 6% - - - 
quality of the reports 50% 50% - - - - 
timing of the  
publication 
47% 35% 18% - - - 
type of notification 56% 39% - - - 6% 
 
Quality of the reports 
The survey participants were asked to rate the quality of the reports. The 
items were total quality, clarity, comprehensibility and scientific quality 
89% evaluated the overall quality of the reports to be ‘very good’ or ‘good’. 
The scientific quality and comprehensibility of the reports was ‘very good’ 
for 61% and ‘good’ for 39%. For 89% the reports were in terms of clarity 
‘very good’ and for 11% ‘good’.  
Application of HSO reports 
71% of the participants said that they were using the reports of LBI-HTA to 
make informed decisions about applying new anti-cancer drugs and/or re-
funding expenses of new drugs. 60% of the participants responding with 
‘yes’ to this question were pharmacists, 20% were medical directors, 10% 
were scientists and 10% were managers. No physician answered this ques-
tion. 
Why are HSO reports not used? 
6 interviewees stated that they were not using the reports provided by LBI-
HTA. Reasons were: lack of clear recommendations (27%), publication lan-
guage (English) (18%), not or few relevant for their current job position 
(18%), publication date (18%), too much information (9%), no clear distinc-
tion within the reports (9%) or other reasons e.g. lack of brief description of 
recommendations or not relevant for work (36%).  
 
89% rated the total 
quality of the reports to 
be very good or good 
71% of the interviewees 
are using the reports 
recommendations  
are lacking 
English language as 
hindrance 
too much information 
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Benefit of HSO  
The interviewees were asked for which categories HSO has proofed most 
helpful.  
Figure 4.1-6: Type of support provided to readership of HSO reports 
21% of the interviewees stated that HSO reports were an information source 
for new anti-cancer drugs, 16% said that they reduced time because they 
give an overview about important results, 14% said that the reports pre-
sented unsolved questions related to new anti-cancer therapies, for 12% the 
reports aided in budget planning or helped to get an overview about the 
most important authorisation studies. 12% said that HSO reports provided 
good references for a more detailed research, 6% stated that HSO reports 
were a decision support to reimburse new drugs, 5% said they saved costs 
because no further money is needed for research and 3% said the reports 
provided support prior to the application of new drugs. 
 
HSO reports are mostly 
used as an information 
source about new anti-
cancer drugs 
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Which professional groups use HSO reports? 
Mainly pharmacists (53%) used HSO reports, followed by medical directors 
(20%), managers (13%), health scientists (7%) and doctors (7%). 
Figure 4.1-7: Professional groups using HSO reports 
Which professional group uses HSO reports for which purposes?  
Pharmacists stated that HSO reports were mostly used as an information 
source for new drugs (see Table 4.1-5). Furthermore they stated that HSO 
reports also reduced time and explicitly raised still unresolved questions. 
Medical directors said that the reports were used as information source, re-
duce time and support budget planning. Doctors said that the reports of-
fered an overview of important authorisation studies, provided good refer-
ences for detailed research, reduced time and served as an information 
source. Scientists stated that the reports saved costs for further research, 
provided good references for detailed research and were used as decision 
support to implement new drugs. Administrators used the reports mainly as 
information source and as decision support document but they also valued 
to learn about open questions. 
information source for 
pharmacists, medical 
directors and managers  
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Table 4.1-5: Categories that support readers of HSO reports 
 totally 
agree agree partly agree less agree 
totally  
disagree 
not able 
to judge 
supportive in applying  
of new drugs 29% 47% 12% 6% - 6% 
supportive in refunding  
of new drugs 19% 38% 13% 7% - 19% 
supportive in budget  
planning 21% 36% 29% 7% - 7% 
information source about 
innovative anti-cancer 
therapies 
39% 56% - 6% - - 
enables elaboration 
through listing of  
important research 
38% 50% 6% 6% - - 
information about authori-
sation status of drugs 31% 44% 13% 13% - - 
gives an overview about 
other treatment options 33% 39% 22% 6% - - 
informs about benefits and 
risks of new drugs 35% 53% 12% - - - 
 
 
Relevance of drugs assessed 
94% of the responders said that the drugs were of relevance. There was no 
response to the question which additional drugs would have been of particu-
lar relevance. 
Results 
LBI-HTA | 2012 37 
Type of notifcation about new HSO reports 
44% of HSO report readers stated to be notified by email-alerts of the LBI-
HTA. 22% said being informed about new reports by the institute’s newslet-
ter, 19% were searching on the website of LBI-HTA and only 6% were 
searching the internet or databases. In 3%, email-alerts were forwarded by 
colleagues (see Figure 4.1-8). 
Figure 4.1-8: Distribution - type of notification 
Feedback  
At the end of the survey all interviewees were asked to give feedback on HSO 
in general and to make suggestions for changes and improvements for future 
HSO reports. 39% (n=14) of the survey participants gave feedback. In gen-
eral there were 64% positive feedbacks, 27% suggestions for improvements 
and 9% negative feedbacks. The 14 positive statements were: reports are im-
portant (29%), informative (21%), offered impartial information (21%), gave 
a good overview about anti-cancer drugs (14%) and 7% were very satisfied 
with the reports. The two negative comments made were that the reports 
were not important and that physicians would be able to assess new drugs 
based on the licensing documents provided by the EMA alone. Last but not 
least, the 6 suggestions for improvements were: short summary of the report 
in German, faster assessment, inclusion of a cost-benefit analysis, display of 
side-effects and quality-of-life aspects and assessments of long established 
anti-cancer drugs. 
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4.2 Environmental analysis 
Searching the databases and by screening the websites of HTA institutions, 
10 institutes performing assessment on anti-cancer drugs were identified. 
These were: 
 Drug Commission of the German Medical Association (AKDAE),  
 Canadian Agency for Drugs and Technologies in Health (CADTH),  
 Dutch Health Care Insurance Board (CVZ),  
 French National Authority for Health (HAS),  
 German Institute for Quality and Efficiency in Health Care (IQWIG),  
 The National Centre for Pharmacoeconomics in Ireland (NCPE),  
 UK’s Coordinating Centre for Health Technology Assessment 
(NETSCC),  
 UK’s National Horizon Scanning Centre (NHSC),  
 National UK’s Institute for Health and Clinical Excellence (NICE) 
and the 
 Scottish Medicines Consortium (SMC). 
 
Overall results of searches in the databases and screening of websites 
Table 4.2-1 shows the overall search result of method 1 (research performed 
in the following databases: EuroScan, EUnetHTA, INAHTA and CRD HTA 
database) and method 2 (screening of the websites of identified HTA insti-
tutes for assessment reports which were not listed in the databases).  
Out of 24 reports (updates were not considered), the LBI-HTA was 2 times 
the only institute having published an early assessment report (S-1 and Ve-
murafenib). 5 reports (Panitumumab, Ipilimumab, Cabazitaxel, Axitinib, 
Vemurafenib) had been published prior to approval by the EMA, 18 reports 
within 6 months after EMA approval and 4 reports 7-20 months after EMA 
approval. Of note though, after the first 5 drugs (Azacitidine, Cetuximab, 
Everolimus, Rituximab and Ibritumomab tiuxetan) had been assessed by the 
LBI-HTA, the filtration and identification criteria were re-defined in order 
to identify drugs earlier in their life cycle (nearer to approval by EMA). The 
drug Plerixafor was commissioned by the government (MoH/ Ministry of 
Health) and was therefore not identified within HSO. 
The following list represents a ranking of institutes based on the thematic 
overlap with the topics assessed by the LBI: 
 NHSC: 19 reports (all reports prior to EMA marketing approval) 
 SMC: 10 reports (3 reports were published within 6 months, 1 report 
prior to EMA marketing approval and 6 between 7-32 months) 
 AKDAE: 9 reports (7 reports within 6 months and 2 reports were pub-
lished 7 months after EMA marketing approval) 
 NICE: 8 reports (1 report within 6 months after EMA marketing ap-
proval and 7 between 7-27 months) 
 HAS: 5 reports (3 reports were published within 6 months after EMA 
marketing approval and 2 reports between 7-12 months) 
 NETSCC: 3 reports (within 6 months after EMA marketing approval) 
LBI-HTA was 2 times the 
single institute having 
published an early 
assessment report 
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 NCPE: 3 reports (1 report within 6 months and 2 reports 7-17 months 
after EMA marketing approval) 
 IQWiG: 3 reports (1 report within 6 months and 2 reports 7-12 
months after EMA marketing approval) 
On average, the reports provided by LBI-HTA were published within 4 
months after approval by the EMA. NHSC published all its 19 reports prior 
to EMA approval. The 10 reports by SMC were published within 10 months 
after EMA approval. AKDAE’s reports were published within 5 months and 
reports provided by NICE within 14 months after EMA approval. The 5 
drug assessment reports of HAS were published on average within 5 months 
of EMA approval. NETSCC published its 3 reports within 3 months and 
IQWiG followed with 8 months. NCPE’s reports published the 3 reports on 
average within 11 months.  
 
 
HSO reports were on 
average published 
within 4 months after 
approval by the EMA 
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Table 4.2-1: Overview of other assessment reports on drugs assessed by LBI-HTA; including drug approval dates of FDA, EMA and TGA  
Drug Indication FDA approval date EMA approval date TGA approval date Early assessment reports of other HTA institutes 
Azacitidine Myelodysplastic syndrome 05/2004 12/2008 NA 
NHSC 09/2007 (prior to EMA approval) 
HAS 04/2009 (4 months after EMA approval) 
LBI-HTA 08/2009 (8 months after EMA approval) 
NICE 03/2011 (27 months after EMA approval) 
SMC 08/2011 (32 months after EMA approval) 
Cetuximab EGFR-expressing NSCLC 02/2004 07/2009 refusal of  market authorisation Under evaluation 
NHSC 08/2006 (prior to EMA refusal) 
LBI-HTA 09/2009 (2 months after EMA refusal) 
Everolimus 2
nd –line therapy for ad-
vanced/metastatic kidney cancer 03/2009 08/2009 NA 
NHSC 04/2008 (prior to EMA approval) 
LBI-HTA 09/2009 (1 month after EMA approval) 
NETSCC 11/2009 (3 months after EMA approval) 
AKDAE 11/2009 (3 months after EMA approval) 1 
HAS 01/2010 (5 months after EMA approval) 
NICE 04/2011 (20 months after EMA approval) 
Rituximab 1
st- and 2nd- line chronic lymphocytic 
leukemia 02/2010 01/2009 05/2010 
NHSC 09/2007 (prior to EMA approval)  
NETSCC 01/2009 (around EMA approval) 
NICE 07/2009 (1st line; 6 months after EMA approval) 
AKDAE 05/2009 (1st line; 4 months after EMA approval) 1 
LBI-HTA 10/2009 (9 months after EMA approval) 
HAS 01/2010 (12 months after EMA approval) 
Ibritumomab tiuxetan consolidation therapy for follicular lymphoma 02/2002 04/2008 NA 
SMC 07/2007  (prior to EMA approval) 
LBI-HTA 12/2009 (20 months after EMA approval) 
Gefitinib 1st-line NSCLC 05/2003 06/2009 06/2010 
NETSCC 11/2009 (5 months after EMA approval) 
HAS 11/2009 (5 months after EMA approval) 
LBI-HTA 12/2009 (6 months after EMA approval) 
NICE 07/2010 (1st line; 13 months after EMA approval)  
NCPE 11/2010 (17 months after EMA approval)  
Trabectedin  2
nd-line recurrent platinum-sensitive 
ovarian cancer NA 09/2009 
Withdrawn by the 
sponsor 
NHSC 12/2007  (prior to  EMA approval) 
LBI-HTA 11/2009 (2 months after EMA approval) 
AKDAE 03/2010 (6 months after EMA approval) 1 
SMC 08/2010 (11 months after EMA approval) 
NICE 04/2011 (19 months after EMA approval) 
                                                             
1 Publication language is German 
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Plerixafor 
autologous stem cell transplantation in 
patients with lymphoma and multiple 
myeloma 
12/2008 07/2009 05/2010 
NHSC 12/2007 (for multiple myeloma; for lymphoma prior 
to EMA approval) 
HAS 12/2009 (5 months after EMA approval) 
SMC 12/2009 (5 months after EMA approval) 
LBI-HTA 03/2010 (8 months after EMA approval) 
Lapatinib 1
st-line advanced/metastatic breast 
cancer 01/2010 05/2010 06/2010 
NHSC 01/2010 (prior to approval) 
LBI-HTA 05/2010 (around EMA approval) 
AKDAE 12/2010 (7 months after EMA approval) 1  
Bendamustin 
Indolent non-Hodgkin’s lymphoma 
(NHL), chronic lymphocytic leukaemia 
(CLL), multiple myeloma (MM) 
03/2008 
03/2010 - Approval not 
granted for all European 
countries 
NA LBI-HTA 07/2010 (4 months after refusal by EMA) NICE 10/2010 (7 months after refusal by EMA) 
Panitumumab 1
st-line treatment of metastatic colo-
rectal cancer 09/2006 
11/2011  conditional 
marketing authorisation 12/2011 
NHSC 06/2008 (prior to EMA conditional marketing  
authorisation) 
LBI-HTA 06/2010 (prior to EMA conditional marketing  
authorisation) 
Trastuzumab 1st-line advanced gastric cancer 10/2010 01/2010 09/2010 
NHSC 09/2007 (prior to EMA approval) 
LBI-HTA 05/2010 (4 months after EMA approval) 
SMC  07/2010 and resubmission in 01/2011 (6 months after 
EMA approval) 
NICE 11/2010 (10 months after EMA approval)  
SMC 01/2011 (12 months after EMA approval) 
and 07/2010 
Pazopanib 1
st line therapy of locally advanced 
and/or metastatic renal cell carcinoma 10/2009 06/2010 06/2010 
NHSC 04/2008 (prior to EMA approval) 
LBI-HTA 10/2010 (4 months after EMA approval) 
AKDAE 12/2010 (6 months after EMA approval) 1 
NICE 02/2011 (8 months after EMA approval) 
SMC 03/2011 (9 months after EMA approval) 
HAS 02/2011 (8 months after EMA approval) 
Ipilimumab Pre-treated patients with ad-vanced/metastatic melanoma 03/2011 07/2011 07/2011 
NHSC 04/2008 (prior to EMA approval) 
LBI-HTA 12/2010 (8 months prior to EMA approval) 
NCPE 09/2011 (2 months after EMA approval) 
AKDAE 11/2011 (4 months after EMA approval)  
Nilotinib 
1st-line treatment of Philadelphia 
chromosome positive chronic myeloid 
leukemia in the chronic phase 
06/2010 12/2010 08/2011 
NHSC 06/2008 (prior to EMA approval) 
LBI-HTA 01/2011 (1 month after EMA approval) 
SMC 07/2011 (7 months after EMA approval) 
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Cabazitaxel 2
nd line chemotherapy for castration-
resistant metastatic prostate cancer 06/2010 03/2011 02/2012 
NHSC 04/2009 (prior to EMA approval) 
LBI-HTA 02/2011 (1 month prior to EMA approval) 
AKDAE 08/2011 (5 months after EMA approval) 
SMC 10/2011 (7 months after EMA approval) 
IQWiG 01/2012  (12 months after EMA approval) 1 
NCPE 03/2012 (14 months after EMA approval) 
Dasatinib 
1st-line treatment of Philadelphia-
chromosome positive chronic myeloid 
leukemia in the chronic phase 
11/2010 12/2010 07/2011 NHSC 09/2009 (prior to EMA approval) LBI-HTA 02/2011 (2 months after EMA approval) 
Eribulin 3
rd- or  late- line mono-therapy for ad-
vanced/metastatic breast cancer 11/2010 03/2011 NA 
NHSC 04/2009 (prior to EMA approval) 
LBI-HTA 06/2011 (3 months after EMA approval) 
AKDAE 10/2011 (7 months after EMA approval) 1 
SMC 10/2011 (7 months after EMA approval) 
IQWiG 01/2012 (10 months after EMA approval) 1 
S-1 1
st-line therapy for patients with ad-
vanced non-small cell lung cancer NA 03/2011 NA LBI-HTA 07/2011 (4 months after EMA approval) 
Abiraterone acetate 
2nd-line therapy for the treatment of 
metastatic castration-resistant pros-
tate cancer after docetaxel therapy 
04/2011 09/2011 NA 
NHSC 05/2010 (prior to EMA approval) 
LBI-HTA 11/2011 (2 months after EMA approval) 
AKDAE 11/2011 (2 months after EMA approval) 1 
IQWiG 12/2011  (3 months after EMA approval) 1 
SMC 02/2012 (5 months after EMA approval) 
Axitinib 2
nd- line treatment of metastatic renal 
cell carcinoma (mRCC) 01/2012 NA NA 
NHSC 08/2010 (prior to EMA approval) 
LBI-HTA 01/2012 (prior to EMA approval) 
Erlotinib 
1st- line treatment of patients with lo-
cally advanced or metastatic non-small 
cell lung cancer with EGFR activating 
mutations 
NA 09/2011 11/2010 
AHRQ 11/2005 (prior EMA approval) 
NHSC 08/2010 (prior to EMA approval) 
NETSCC 11/2011 (2 months after EMA approval) 
LBI-HTA 01/2012 (4 months after EMA approval) 
Vemurafenib BRAF V600E mutation positive ad-vanced/metastatic melanoma 08/2011 02/2012 NA LBI-HTA 01/2012 (1 month prior to EMA approval) 
Everolimus unresectable or metastatic neuroendo-crine tumours of pancreatic origin 05/2011 08/2011 NA 
NHSC 05/2008 (prior to EMA approval) 
LBI-HTA 12/2011 (4 months after EMA approval) 
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Overview on organisations with anti-cancer drug assessment reports  
NHSC 
The NIHR UK’s National Horizon Scanning Centre (NHSC) is funded by 
the National Institute for Health Research (NIHR) and aims to provide key 
policy makers with advance notice of selected new and emerging health 
technologies that might require evaluation, consideration of clinical and cost 
impacts, or modification of clinical guidance up to 2-3 years prior to launch 
on the National Health Service (NHS) in England. The scope of the horizon 
scanning activity includes pharmaceuticals, medical devices and equipment, 
diagnostic tests and procedures, therapeutic interventions, rehabilitation 
and therapy, and public health activities [14].  
The reports published by NHSC contain information about target group, 
technology description, innovation and/or advantages, availability, launch 
or marketing and licensing plans, relevant guidance, clinical need and bur-
den of disease, existing comparators and treatments, efficacy and safety, es-
timated cost and cost impact. 
SMC 
The purpose of the Scottish Medicines Consortium (SMC) is to accept for 
use those newly licensed drugs that clearly represent good value for money 
to NHS Scotland. SMC analyses information supplied by the drug manufac-
turer on the health benefits of the drug and justification of its price. As the 
NHS has limited resources, SMC works to make sure that those drugs which 
represent good value for money are accepted for routine use as quickly as 
possible so that they can benefit patients. The Consortium is made up of 
lead clinicians, pharmacists and health economists together with representa-
tives of health boards, the pharmaceutical industry and the public [15]. The 
horizon scanning function, introduced in 2005, is now an established ele-
ment of SMC's remit. The aim is to improve financial planning at Health 
Board level through the provision of early intelligence on new medicines in 
development. The horizon scanning team, comprising pharmacists and 
management accountants, gathers intelligence on these medicines through 
engagement with clinical specialists across Scotland as well as the pharma-
ceutical industry [15]. 
The reports contain information about indication, dosing information, 
product availability date, summary of evidence on comparative efficacy, 
summary of evidence on comparative safety, summary of clinical effective-
ness issues, summary of comparative health economic evidence, summary of 
patient and public involvement, additional information: guidelines and pro-
tocols, comparators, cost of relevant comparators, budget impact. 
AKDAE 
The Drug Commission of the German Medical Association (DCGMA; AK-
DAE) is the scientific expert committee for drug-related matters of the 
German Medical Association. It consists of 40 full members and approxi-
mately 100 associate members from all areas of medicine and pharmacy. The 
AKDAE is financed by the German Medical Association (BÄK) and the Na-
tional Association of Statutory Health Insurance Physicians (KBV). All 
members work voluntarily for the AKDAE. The main tasks of the commis-
sion are providing the medical profession with various and up-to-date in-
formation on rational drug therapy and drug safety, advising the BÄK in 
fundamental questions of pharmaceutical policy and special requests of phy-
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sicians and official institutions of health care, reporting, documentation and 
assessment of adverse drug reactions [12]. 
The reports provided by AKDAE contain information about indication, as-
sessment, clinical studies, side-effects, contraindications, warning notices, 
target audience, dosage and costs. 
NICE 
The National Institute for Health and Clinical Excellence (NICE) was set 
up in 1999 to reduce variation in the availability and quality of NHS treat-
ments and care. The evidence-based guidance and other products help re-
solve uncertainty about which medicines, treatments, procedures and de-
vices represent the best quality care and which offer the best value for 
money for the NHS. All NICE guidance and every NICE quality standard is 
developed by an independent committee of experts including clinicians, pa-
tients, carers and health economists. The guidance is considered and ap-
proved by the NICE Guidance Executive, a committee made up of NICE ex-
ecutive directors, guidance center directors and the communications direc-
tor, prior to publication. The Citizens Council, comprising 30 members of 
the public, provides NICE with advice that reflects the public perspective on 
what are often challenging social and moral issues raised by NICE guidance 
[16].  
NICE reports contain information about the technology, manufacturer’s 
submission, consideration of the evidence, implementation, related NICE 
guidance and review of guidance. 
HAS  
The Haute Autorité de Santé (HAS) - or French National Authority for 
Health - was set up by the French government in August 2004 in order to 
bring together a number of activities designed to improve the quality of pa-
tient care under a single roof and to guarantee equity within the health care 
system. HAS activities are diverse. They range from assessment of drugs, 
medical devices, and procedures to publication of guidelines to accreditation 
of health care organisations and certification of doctors. All are based on 
rigorously acquired scientific expertise. Training in quality issues and in-
formation provision are also key components of its work program. HAS is 
not a government body. It is an independent public body with financial au-
tonomy. It is mandated by law to carry out specific missions on which it re-
ports to Government and Parliament. It liaises closely with government 
health agencies, national health insurance funds, research organisms, unions 
of health care professionals, and patients' representatives.  HAS has been 
built on 3 founding principles: a very broad field of action, which means that 
it can compare a range of health care initiatives; a high degree of scientific 
rigor; and independence [17]. 
The reports contain information about indication, dosage, similar medicinal 
products, analysis of available data and transparency committee conclu-
sions. 
NETSCC  
NETSCC is another institute being funded by the NIHR and was estab-
lished at the University of Southampton in 2008. UK government support 
for medical research is channeled primarily through the NIHR and the 
Medical Research Council (MRC). Broadly speaking, the NIHR funds later-
phase health research, which has the potential to influence the delivery of 
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health care to patients, while the MRC supports basic and early clinical re-
search. The two bodies work closely together, overseen by the Office for Stra-
tegic Coordination of Health Research to ensure that there is a continuum of 
research opportunities along the translational pathway and to ensure activi-
ties are coordinated. NETSCC manages five distinct but interconnected 
evaluation research programs:- Efficacy and Mechanism Evaluation (EME) 
program- NIHR Health Services and Delivery Research (HS&DR) program- 
NIHR Health Technology Assessment (HTA) program- NIHR Public 
Health Research (PHR) program- NIHR Systematic Reviews (SR)  program.  
NETSCC’s reports contain information about: summary, background, cri-
tique of manufacturer’s definition of decision problem, clinical effective-
ness, economic evaluation, additional analysis undertaken by the ERG, end 
of life treatment criteria and discussion [18]. 
NCPE  
The National Centre for Pharmacoeconomics conducts the HTA of pharma-
ceutical products for the Health Service Executive (HSE) in Ireland in col-
laboration with the HSE Corporate Pharmaceutical Unit (HSE-CPU).  The 
aim of the center is to promote expertise in Ireland for the advancement of 
the discipline of pharmacoeconomics through practice, research and educa-
tion [19].  
The cost-effectiveness reports contain information about indication, cost ef-
fectiveness, comparative medicines, sensitivity analysis and budget impact 
analysis. 
IQWiG 
IQWiG is an independent scientific institute in Germany that investigates 
the benefits and harms of medical interventions for patients. IQWiG regu-
larly provides information about the potential advantages and disadvantages 
of different diagnostic and therapeutic interventions. 
The reports contain information about added benefit, results of other re-
ports, probability and extent of added benefit, study design and population, 
medical benefit and added medical benefit [20]. 
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5 Limitations 
There are some major limitations of this impact analysis: 
The survey: By reasons that the survey was sent to HSO email-alert recipi-
ents only, a highly selected group of people was targeted. Those who re-
sponded – because of the low response rate only a minority – were rather 
positive about the HSO reports. A responder bias is thus very likely. Addi-
tionally, although the HSO reports are written in English, the primary target 
group of the email-alerts are German speaking (Austrian) recipients. It is 
therefore not possible to draw any generalizing conclusions on the impact of 
HSO reports on both national as well as international readers. 
The download-analysis: The download rates must not necessarily represent 
the number of total downloads, since the reports can be downloaded only 
once but may be disseminated further, in printed or electronic form. The 
calculated download rates therefore represent the minimum number of 
downloads. 
Furthermore, calculating the average monthly downloads is very dependent 
on the time published. Clearly, recently published HSO reports have higher 
average rates per month, since most downloads happen in the first months. 
On the other hand, newer reports will inevitably have fewer absolute 
downloads.  
The environmental analysis: It was not possible to identify all HTA institu-
tions publishing (early) assessment reports since screening websites is a 
never-ending process. Additionally, not all publications are entered in the 
HTA databases and many institutions might not publish their reports online 
and/or in English or German. Therefore, several reports will be missing 
since they are written in other languages or are not publicly available. Addi-
tionally, the scope and methods as well as objectives of reports differ (infor-
mation for rational decision-making only or basis for reimbursement or for 
price-negotiations). Therefore a comparison of those reports proves difficult. 
Finally, an internal evaluation is always more prone to bias than an external 
evaluation, because findings are - to a certain extent - interpreted in favour 
of the HSO program.  
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6 Discussion and outlook 
The objectives of the HSO are to identify and assess anti-cancer drugs early 
and to support hospitals in rational decision making and prospective budget 
planning. More than one third of the survey participants said that they did 
not know HSO although they receive email-alerts about newly published 
HSO reports regularly. Whether they did not receive the email-alerts, were 
recently added to the email-list, were not reading the email-alerts or were 
not downloading the reports remains unknown. One explanation could be 
that the survey participants did not recognise HSO at all or were not aware 
that the decision support documents are part of HSO.  
The general result of the survey is that there were hardly any decision-
makers of hospitals - the intended target audience of HSO - participat-
ing/answering. Most survey participants were pharmacists or members of 
drug commissions. The few medical directors participating in the survey 
stated that they used HSO reports for rational decision making on costly 
drugs. Nevertheless the awareness about HSO and usage of HSO reports by 
hospitals could be higher than evaluated with the online survey. 
The download analysis showed nearly 14,000 website-views and nearly 7,000 
downloads, with 25 downloads on average per month and 250 to 350 times 
(with exceptions in both directions) in absolute terms. This is – compared to 
other (comprehensive) LBI-HTA reports – the average [7]. Even though the 
feedback on the HSO reports in the survey was generally positive, sugges-
tions for improvements are reaching from a short summary in German to 
provision of a cost-benefit analysis. 
To increase the awareness of the HSO program marketing activities and the 
email-list could be reviewed and further populated with additional (interna-
tional) recipients. Also, a button on the website to subscribe to the email-
notifications might prove useful. 
One intention for this impact analysis was to find out who the recipients of 
HSO-reports were and how often or for what reasons the reports were used 
(downloaded). The second objective was to clarify the market position 
(=profile) of the LBI-HTA’s HSO program and to identify further potential 
for international collaborations. The general finding of this report is that 
HSO in its form is the only horizon scanning system concentrating solely on 
anti-cancer drugs. The HSO reports are published close to EMA-approval 
and in contrast to other horizon-scanning programs the reports are more 
elaborated in terms of a critical commentary. Finally, the environmental 
analysis showed that LBI-HTA is ahead with its early assessments of anti-
cancer drugs. The reports were on average published within 4 months after 
EMA approval and, besides the NHSC, the LBI-HTA was amongst the first 
HTA institutes having published early assessment reports. 2 times it was the 
only HTA institute having published a report. 
 
Based on the POP database, developed in EUnetHTA Joint Action 1 (2010-
2012), we know that 10-12% of all European HTA-products are identical. 
Most of those identical HTAs are drug-evaluations. Based on this knowl-
edge, the LBI-HTA has started actively to search for collaboration partners 
in order to reduce this enormous redundancy. 8 of such collaborations have 
taken place among 5 HTA-agencies in the last 2 years. More will come with 
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EUnetHTA Joint Action 2 (2012-2015) which will apply a standard method-
ology within a standard format, as piloted on Pazopanib in EUnetHTA Joint 
Action 1. 
 
Table 6-1: Collaborations on anti-cancer drugs in Europe 
LBI-HTA + AHTAPol: Dasatinib (Sprycel®) for the 1st-line treatment of Phila-
delphia-chromosome positive chronic myeloid leukaemia in the chronic 
phase; April 2011 
LBI-HTA + HTA Centre Bremen: Second-line chemotherapy with Cabazitaxel 
(Jevtana®) for the treatment of castration-resistant metastatic prostate can-
cer; May 2011 
LBI-HTA + AHTAPol + UVEF (Reg. Veneto): Eribulin (Halaven®) as third- or 
late-line monotherapy for advanced/metastatic breast cancer, July 2011 
LBI-HTA + HTA Centre Bremen: Abiraterone acetate (ZytigaTM) as 2nd-line 
therapy for the treatment of metastatic castration-resistant prostate cancer 
after docetaxel therapy; December 2011 
LBI-HTA + ULSS20: Vemurafenib for patients with BRAF V600E mutation 
positive advanced/metastatic melanoma; January 2012 
LBI-HTA + ULSS20: Axitinib (AG 013736, Inlyta®) for the 2nd-line treatment 
of metastatic renal cell carcinoma; February 2012 
LBI-HTA + UVEF (Reg. Veneto) + AHTAPol: Lenalidomide (Revlimid®) for 
the treatment of low /intermediate-1 risk myelodysplastic syndrome with 
chromosome 5q deletion; May 2012 
LBI-HTA + ULSS20: Ipilimumab for the first line therapy of ad-
vanced/metastatic melanoma (ongoing)  
 
Since the need of different health care systems as well as stakeholders will 
always differ, building on each other’s assessment (from assessments of 
emerging (pre-approval) over the assessment of new drugs (around approval) 
to assessments for reimbursement or cost-negotiation decisions) might be 
the way forward. 
 
and building on  
each other’s HTAs 
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8 Appendix 
8.1 Online survey 
Table 8.1-1: Questionnaire of the online survey 
Welche Funktion u¨ben Sie aus? 
In welchem Bundesland arbeiten Sie? 
Sind Sie in Entscheidungen u¨ber Einsatz und/oder Kostenerstattung von onkologischen Medikamenten 
involviert? 
Welche Quellen verwenden Sie, um Entscheidungen zum Einsatz und/oder zur Kostenerstattung von 
neuen Onkologika treffen zu ko¨nnen? 
Kennen Sie das Arbeitsprogramm „Fru¨hbewertung neuer Onkologika“ (auch Horizon Scanning in der 
Onkologie genannt) vom LBI-HTA? 
Wie zufrieden sind Sie allgemein mit den vom LBI-HTA kostenlos zur Verfu¨gung gestellten Berichten 
neuer onkologischer Medikamente? 
Verwenden Sie die Berichte des LBI-HTA um eine Entscheidung zum Einsatz und/oder zur Erstattung von 
neuen Onkologika zu treffen? 
Bitte kreuzen Sie in untenstehender Tabelle an, wie sehr Sie den angefu¨hrten Aussagen zustimmen/nicht 
zustimmen: Die Berichte zur Fru¨hbewertung von neuen Onkologika… 
Bitte bewerten Sie die Qualita¨t der Berichte auf der untenstehenden Skala: 
Bewerten Sie bitte die einzelnen Kapitel der Berichte. Wie ist der Informationsgehalt der einzelnen 
Kapitel? 
Sind die ausgewa¨hlten Arzneimittel in den Berichten fu¨r Sie relevant? 
In welcher Hinsicht helfen Ihnen die Berichte bei Ihrer Arbeit? 
Welche Informationen wu¨rden Sie sich zusa¨tzlich in den Berichten wu¨nschen? 
Wie erfahren Sie von den Berichten? 
Welche anderen Informationsquellen bzw. Publikationen von Fru¨hbewertungen von neuen 
onkologischen Medikamenten kennen oder verwenden Sie? 
Abschliessend mo¨chten wir Sie um ein kurzes Feedback (Anregungen, Kommentare und/oder 
Verbesserungsvorschla¨ge) zum Arbeitsprogramm „Fru¨hbewertung neuer Onkologika“ bitten: 
 
8.2 Databases used for the environmental 
analysis 
CRD HTA database  
Centre for Reviews and Dissemination (CRD) is part of the National Insti-
tute for Health Research (NIHR) and is a department of the University of 
York in Great Britain. NIHR provides research-based information about the 
effects of health and social care interventions via their databases and under-
takes systematic reviews evaluating the research evidence on health and 
public health questions of national and international importance. The find-
ings of the research outputs are widely disseminated and have impacted 
health care policy and practice, both in the UK and internationally. The 
CRD databases provide decision-makers with access to over 9,000 quality as-
sessed systematic reviews, over 11,000 economic evaluations, over 10,000 
database focuses on 
completed and ongoing 
HTA from around the 
world 
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summaries of completed and ongoing health technology assessments, sum-
maries of all Cochrane reviews and summaries of Campbell reviews. The 
CRD HTA Database focuses on completed and ongoing health technology 
assessments from around the world. Database content is supplied by the 52 
members of the International Network of Agencies for Health Technology 
Assessment (INAHTA) and 20 other HTA organisations around the world. 
Details of other on-going systematic reviews are also registered on the HTA 
database. All new content is checked, proof read and published on the data-
base by CRD [13]. 
 
International Network of Agencies for Health Technology 
Assessments (INAHTA)  
INAHTA was established in 1993 and has grown to 53 member agencies 
from 29 countries. The Network stretches from North and Latin America to 
Europe, Asia, and Australia. INAHTA has several publications online: The 
Brief series is intended as a forum for member agencies to present overviews 
of recently published reports. INAHTA briefs are published regularly and 
placed on the INAHTA website as soon as they become available. HTA 
Checklists are an aid to furthering a consistent and transparent approach to 
HTA. They also provide information on the purpose, methods, and contents 
of an HTA report. Joint projects involve the member agencies in collabora-
tive efforts to evaluate medical technologies of mutual interest [11]. 
INAHTA offers research in its own database and links to the CRD HTA da-
tabase. 
 
EuroScan International Network (EuroScan)  
The International Information Network on New and Emerging Health 
Technologies (EuroScan International Network) is a collaborative network 
of member agencies for the exchange of information on important emerging 
new drugs, devices, procedures, programs, and settings in health care. Euro-
Scan International Network is a collaborative network that collects and 
shares information on innovative technologies in health care in order to 
support decision-making and the adoption and use of effective, useful and 
safe health-related technologies. It is the principal global forum for the shar-
ing and development of methods for the early identification and early as-
sessment of new and emerging health-related technologies and predicting 
their potential impact on health services and existing technologies [9]. Since 
its inception in 1998, EuroScan has established a common terminology and 
prioritisation criteria; undertaken a comparative analysis of systems; devel-
oped a publicly-accessible search of the EuroScan database to facilitate ac-
cess to reports published by member agencies on their own websites. 
 
EUnetHTA  
The EUnetHTA collaboration was launched in November 2008 and is im-
plementing the proposal for a sustainable, permanent collaboration for HTA 
in Europe. Uniting government-appointed organisations from EU Member 
States, EEA and EFTA countries and a large number of relevant regional 
agencies and non-for-profit organisations that produce or contribute to 
HTA, the EUnetHTA collaboration focuses on HTA in Europe to facilitate 
efficient use of resources available for HTA, to create a sustainable system of 
INAHTA links to the 
CRD database 
developed a database to 
facilitate access to 
reports published 
POP database aims to 
reduce duplication and 
facilitate collaboration 
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HTA knowledge sharing, and to promote good practice in HTA methods and 
processes [10]. The POP (Planned and Ongoing Projects) database allows 
HTA agencies to share with each other information on planned and ongoing 
projects conducted at each agency. The aim of the database is to reduce du-
plication and facilitate collaboration among HTA agencies. 
 
Health Technology Assessment International (HTAi)   
HTAi is the global scientific and professional society for all those who pro-
duce, use, or encounter HTA. HTAi embraces all stakeholders, including re-
searchers, agencies, policymakers, industry, academia, health service pro-
viders, and patients/consumers, and acts as a neutral forum for collaboration 
and the sharing of information and expertise. HTAi is a global network and 
has members from 59 countries and six continents. HTAi is actively commit-
ted to international collaboration, and has signed formal Memoranda of Un-
derstanding with the World Health Organization and the International 
Network of Agencies for HTA (INAHTA) [21]. 
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